There remain issues with benchmarking, attribution, and risk adjustment that CMS needs to address with accountable care organizations (ACOs), said Rob Fields, MD, assistant profession, family medicine and community health, Icahn School of Medicine at Mount Sinai, and senior vice president, chief medical officer, population health at Mount Sinai Health System.
There remain issues with benchmarking, attribution, and risk adjustment that CMS needs to address with accountable care organizations (ACOs), said Rob Fields, MD, assistant profession, family medicine and community health, Icahn School of Medicine at Mount Sinai, and senior vice president, chief medical officer, population health at Mount Sinai Health System.
Transcript
What are some areas for continued improvement in Medicare Shared Savings Program that CMS has not addressed yet?
I think that’s a difficult question. They’ve addressed a lot of the things in part. So, I think there are several major buckets, I think, where systems and other ACOs have concerns. One is around benchmarking. The way that CMS attributes the target price essentially for patients has been challenging and hard to predict. It is improving: things like regional benchmarking, for the most part, is a step in the right direction for most systems, but not across the board. But I think what needs to improve is the predictability. We see pretty significant swings even within the same performance year from baseline, historical benchmarks, to final, reconciled benchmarks. And I think that’s a challenge, especially when you’re talking about risk. If we’re seeing swings of as much as 10% in how the benchmark goes, that’s really difficult to predict. You could be tracking great all year, and then end up upside down in the end in a way that wasn’t predictable. So, that’s a problem and it doesn’t exist in Medicare Advantage, but it absolutely exists in these models.
I think the other piece is attribution still can be challenging. And I don’t know if there’s a perfect solution for that, whether it’s retrospective or prospective and there are models that try to address both. There are ways of perhaps reconciling attribution based on where patients are actually seen and things like that. But I think there needs to be continued work on attribution, as well.
And I think the last one, which is as important as the benchmarking piece, is ability to risk adjust throughout the performance year would be particularly helpful as the population changes. There is certainly significant churn in membership because of attribution. And not being able to adapt the risk adjustment to the new patients that are coming on is perhaps a problem.
What additional innovations would you like to see coming out of CMS?
I would really be interested in things coming out of CMMI [Center for Medicare and Medicaid Innovation] that start to look at how do we pay or how do we finance the social determinants and other nonhealthcare-related services that we all deal with. We are talking about it here at the conference this fall, many sessions discussing how we handle social determinants and how we finance that. And having models that more easily tie the delivery and coordination of those services, which is very much a part of this work, finding a way of connecting that to the financial model, I think, would be an interesting thing to try to work on. But that’s likely more of a CMMI innovation process rather than a true MSSP process.
Science at AACR Aims to Overcome Cancer Care Barriers
April 24th 2025A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
Read More
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More